This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk04: Ladies and gentlemen, thank you for standing by. Greetings and welcome to Inhibit Case Therapeutics' fourth quarter and full year 2023 financial results. At this time, all participants will be in listen-only mode. The question and answer session will follow the formal presentation. Please note that today's conference is being recorded, and if you should require operator assistance, you may press star zero from your telephone keypad. I'll now turn the call over to Alex Lobo, Stern Investor Relations. Alex, you may now begin.
spk02: Thank you, operator. Good morning and welcome to Inhibit Case Therapeutics' fourth quarter and full year 2023 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer, and Garth Lees-Ross, Chief Financial Officer. On March 27th, Inhibit Case issued a press release announcing financial results for the fourth quarter and full year ended December 31st, 2023. We encourage everybody to read yesterday's press release as well as Inhibit Case's annual report on Form 10-K. which has been filed with the SEC. The company's press release and annual report are also available on Inhibicase's website at inhibicase.com. In addition, this conference call is being webcast through the investor relations section of the company's website and will be archived there for future reference. Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, March 28, 2024. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast, except as may be required by applicable securities law. With that said, I would now like to turn the call over to Dr. Milton Werner. Milton, you may begin.
spk00: Thank you, Alex, and thank you, everybody, for joining the call today. Before I begin, I just want to give a round of applause to our outgoing Chief Financial Officer, Joe Frateroli, who is on the call. Tomorrow will be his last day with the company, and we are very grateful for the six years of work that he and I have done together to bring Hibicase where we are. Also to introduce you to our new chief financial officer who will begin on Monday, formally in the job, Garth Lees-Ralph, who will be discussing our financial results. And so with that, really we appreciate everybody joining the call for our discussion of our fourth quarter and full year 2023 financial results and recent clinical and business updates. 2023 was really a year of execution as we made significant advancements across our clinical pipeline, culminating in a recent pre-MDA meeting with the FDA for iKids T01 Pro, and the rapid enrollment of Parkinson's patients in our 201 trial for Rizvodetinib or Rizvo, as we'll refer to it throughout this presentation. We are also evaluating new second-generation molecules arising from our internal medicinal chemistry and external collaborations that could further expand our pipeline and enhance suppression of neurodegeneration or address other diseases that could be benefiting from ablokinase inhibition. While we have much work to do in 2024, we believe that we are well positioned for success and continue to build value for our shareholders. Let's now take a deeper dive into each of our programs, starting with Rizvodetin Able or Rizvo. As you may remember, Rizvo is a potent selective inhibitor of C-able that is administered once daily and that we believe may slow or halt the progression of Parkinson's disease. Our 201 trial is a two-phase trial with an ongoing 12-week double-blinded study across three doses that we believe should be therapeutic, plus a fourth group that is taking a placebo. The trial is approximately 61% enrolled as of March 22nd, with 73 participants, 20 prospective participants in medical screening, and an additional 48 potential participants being evaluated for suitability to initiate medical screening. Additionally, 34 participants have completed the full 12-week dosing period. To date, 15 mild and two moderate adverse events have been observed that may be related to visceral treatment. Two people elected to withdraw from the trial despite having only one or two moderate adverse events. We believe the last patient will be ruled during the summer of 2024. To date, trial recruitment has been successful in our review, generating broad interest within the Parkinson patient community nationwide, allowing for hundreds of unique individuals to be screened by an outside medical staff and referred into our clinical sites prior to entering a medical record review process. in advance of initiation of formal medical screening. We plan to report top-line results from this study in the second half of this year. The 201 trial plans to enroll everyone who continues to meet the eligibility criteria into a 12-month extension study. Although we have completed several of the infrastructure bills to execute this trial, we are still in need of additional financing to begin enrolling participants into the extension study at our clinical sites. As we previously disclosed, the extension study will transition participants from the blinded phase, who will still meet enrollment criteria, to an additional 12 months of treatment, which will also serve the purpose of evaluating our novel commercial tablet formulation for Rizvo that we announced last year. As we continue to establish the potential of Rizvo in Parkinson's disease, we believe it is important to communicate the progress to key stakeholders in the medical and scientific community. In January, we published the Phase 1, 1B data evaluating Rizvo and healthy volunteers and the patients treated with anti-Parkinson medications. That report appeared in the peer-reviewed journal, Journal of Parkinson's Disease. The publication highlighted the safety, the tolerability, and pharmacokinetics of Rizvo across 94 healthy volunteers and 14 participants with Parkinson's Disease in both single ascending dose and multiple ascending dose studies. We found that Rizva demonstrated a favorable safety and tolerability profile for all trial participants with 12 potentially treatment-related adverse events observed, none of clinical significance. Single-dose pharmacokinetics were approximately a year between 12.5 and 200 milligrams for both CMAX and the area under the curve or AUC measurement with no pharmacokinetic difference between healthy volunteers and participants with Parkinson's disease. Exposures of ethos were high relative to other drugs in the same class, same kinase inhibitor class. And of note, we used voluntary lumbar puncture to measure the concentration of Rizvo in cerebral spinal fluid in six participants with or without PDE, which indicated that Rizvo crossed the blood-brain barrier and was persistently present in the central nervous system. While this is a limited data set, we find these results encouraging. Overall, we believe that the totality of the data we've generated to date continues to support the development of RISVO, and we look forward to providing updates on the progress of the 2-1 trial throughout the year. Moving now to IKT-01-PRO, which is a pro-drug formulation of imatinib mesylate that has been designed to improve the safety profile of imatinib. We had a pre-MDA meeting on January 19th of this year with the FDA to discuss the requirements for potential approval of IKT-01 Pro under the 505 statute. We were pleased with the discussion we had with the agency as we begin the process of building our first MDA package, and we plan to seek all 11 blood and stomach cancer indications for which imatinib mesylate has been approved. The FDA review team from the Division of Hematologic Malignancies determined through a review of our clinical data That 600mg and 800mg IKT-O1-pro provided similar exposures to 400mg and 600mg imatinib mesylate, respectively. The review team advised that if we want to seek all the indications for which imatinib has previously been approved, we should measure the safety, tolerability, and pharmacokinetics of IKT-O1-pro that would deliver up to 800mg, the highest approved dose of imatinib mesylate. We plan to evaluate IKT-O1-pro at a 1,200mg dose, which we believe will lead to exposures to imatinib that are similar to 800mg imatinib mesylate. Further, a review team asked that we evaluate whether O1-pro and imatinib are absorbed differently from the gut, so we are initiating a standard preclinical test to further evaluate IKT-O1-pro and imatinib gut absorption, which is a test performed in cell culture. As we continue to advance the elements of the MDA package, we will seek milestone meetings with the FDA to ensure we are meeting manufacturing, scientific, and quality control requirements for approval. Now, before I turn the call over to our incoming Chief Financial Officer, Garth Lees-Wall, to review our financial results for the quarter, I'd like to, again, extend our deepest gratitude from both the Board of Directors and our entire team to Joe Frateroli for his years of service as Chief Financial Officer, and we all wish him best in his retirement. With that said, I'll turn the call over to Garth to review our financial results.
spk01: Thank you, Nelson. Now, let me review our financial results for the year and quarter ended December 31, 2023. Net loss for year ended December 31, 2023 was $19.0 million or $3.57 per share compared to a net loss of $18.1 million or $4.28 per share for the year ended December 31, 2022. Research and development expenses for the full year ended December 31, 2023 with $13.6 million compared to $12.0 million for the full year 2022. The increase was primarily due to a $1.5 million increase for IKT-001-Pro and a decrease of $0.6 million in expenses for RISVO and a net increase of $0.7 million for all other R&D activities. Selling general and administrative expenses for the full year 2023 was $6.7 million compared to $6.2 million for the same period in 2020. The $0.5 million increase was primarily the result of an increase in investor relation costs of $1.0 million, an increase in employee costs of $0.3 million that were partly offset by a decrease in D&O insurance of $0.6 million, a decrease in legal and consulting fees of $0.4 million, and a net increase of $0.2 million in all other selling, general, and administrative . As of December 31, 2023, we had $13.3 million in cash cash equivalents, and marketable securities. We expect that existing cash and cash equivalents will be sufficient to fund operations into the first quarter of 2025. That concludes our financial statements. I'd like to hand the call back over to Milton for closing remarks.
spk00: Thank you, Garth. As we look ahead to 2024, we will continue to take advantage of the recent momentum we have experienced to continue to create value for our shareholders. We believe that the recent feedback from our pre-MDA meeting was constructive as we plan to conduct additional tests and studies to begin to build our first MDA submission package. In addition, we will continue to enroll patients into our 201 trial and expect to provide top-line data from this study in the second half of the year. Our recent publication of early clinical data for Rizvo and Adrenal Parkinson's Disease reinforces our belief that Rizvo could be a transformative treatment for patients with Parkinson's Disease and related disorders. We look forward to continuing to establish ourselves as a leader in the development of treatments for neurodegenerative disease, and we want to thank all our shareholders and trial participants for their continued support as we advance new medicines for patients with high-end medical needs. I would now like to open the call for questions. Operator?
spk04: Thank you. We'll now be conducting a question-and-answer session. If you'd like to ask a question at this time, please press star 1 from your telephone keypad, and the confirmation tone to indicate your line is in the question queue. You may press star two if you'd like to remove your question from the queue. For participants that are using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Thank you. Thank you. Our first question is from the line of Ed White with HC Wainwright. Please proceed with your questions.
spk03: Good morning. This is Steve on for Ed White. So assuming positive data in Parkinson's in the second half, What are the next steps towards approval and timing?
spk00: Well, approval is a little bit hard to gauge. We've been fortunate to be able to enroll the 201 trial at least for this patient population at a faster rate than other studies of its kind in the last three years since COVID emerged. The phase three trial or trials would be run, again, in untreated Parkinson's patients on a larger scale. We'll need to assess the degree of benefit if observed at all three doses of verizimidecinib and to decide whether we're going to have a one or two trial, one or two dose trial for registration purposes. We also think that based on the outcomes of biomarker analysis, and we don't know those outcomes to date, but if biomarkers support what we've seen in the preclinical animal models, there are opportunities to seek accelerated approval designations that could assist and accelerate those Phase 3, 1, or 2 trials that would be necessary for registration. I would guess it's probably a two- to three-year process overall. We would plan, depending on the outcome of the trial that we see this year, to schedule a meeting with the FDA to discuss the parameters of the Phase 3 program. On the manufacturing side, we're well ahead of the game. We are already producing Rizvidectinib on the order of commercial scale. We have a commercial tablet formulation we'll be testing in the extension trial, and assuming that there are no issues that arise from that tablet formulation, we'll be in a very strong position to complete the other requirements of clinical development and enter into an NDA process.
spk03: All right, thank you. And for IKT 001 Pro, can you just comment on the big picture strategy and then any comments on potential partnering?
spk00: So, you know, we have, you know, 001 Pro is a bit of an unusual molecule for us. It's technically a novel chemical entity. We have compositions of matter protection. We evaluated it originally to determine whether technology ideas that we built into that molecule could improve on a well-established, well-tolerated drug substance. And we see hints of that coming through the clinical work that we've done to date. We also seem to have reasonable support at the FDA that could lead to approval through the 505 statute. So along that path, The one qualification is that O1 Pro would be a kind of, in quotations, branded generic. Its earning potential is unknown at the moment, but it's much more modest given that the frontline drug imatinib mesylate is now generic. And there are 15 generic suppliers in the U.S. for that medication. So it depends on how this evolves moving forward. We would be seeking a partner to assist in the cost of of a non-inferiority or superiority trial to further augment the safety knowledge. That trial does not have to be part of any approval process, but we would like to initiate it in the near future because it would be done in the target patient population that have blood or stomach cancers. Separately from that, as we've disclosed previously, we have an interest in evaluating O1Pro as a potential branded product in non-oncology indications And we'll be providing a further update on that underlying strategy in the coming days because we have an upcoming meeting with the FDA on that subject at the end of next week. And I don't want to preempt that announcement, but we'll be saying a little bit more about that in the coming days.
spk03: All right. Thank you. I was going to ask about that meeting. That's all our questions. Thanks.
spk04: Thank you. Seeing no additional questions at this time, this will also conclude today's teleconference. You may now disconnect your lines at this time. We thank you for your participation, and have a wonderful day.
Disclaimer